Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

Hady Ghanem, Hagop Kantarjian, Jorge Cortes, Alfonso Quintás-Cardama, Elias Jabbour

Research output: Contribution to journalReview article

Abstract

Introduction: Chronic myeloid leukemia (CML) is a disease in which outstanding discoveries and achievements have been made over the past two decades. The use of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI) has revolutionized the treatment of this disease and drastically improved its outcomes. Areas covered: Imatinib was the first TKI to be studied and results from the initial IRIS study continues to show major improvement over the historical IFN treatment. More recently, second-generation TKIs, such as dasatinib and nilotinib, and more recently bosutinib proved to be superior to imatinib: higher rates of remission and faster responses. Recently, ponatinib has shown significant efficacy against the most resistant cases of CML, including those who carry the highly resistant T315I mutations. The purpose of this article is to review the data available on different TKIs in the treatment of CML, as well as the emerging data for the treatment of resistant disease. Expert opinion: Early identification of resistant cases and enrollment in clinical trials with new drugs continue to be warranted in the appropriate setting. The use of new therapeutic strategies in an attempt to eradicate the disease will be the main focus of clinical trials in the next decade.

Original languageEnglish (US)
Pages (from-to)607-623
Number of pages17
JournalExpert Opinion on Orphan Drugs
Volume1
Issue number8
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Clinical Trials
Expert Testimony
Therapeutic Uses
Protein Kinase Inhibitors
Mutation
Pharmaceutical Preparations
Imatinib Mesylate

Keywords

  • Bosutinib
  • Chronic myelogenous leukemia
  • Dasatinib
  • Imatinib
  • Nilotinib
  • Novel therapies
  • Ponatinib
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy
  • Pharmacology (medical)

Cite this

Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. / Ghanem, Hady; Kantarjian, Hagop; Cortes, Jorge; Quintás-Cardama, Alfonso; Jabbour, Elias.

In: Expert Opinion on Orphan Drugs, Vol. 1, No. 8, 01.01.2013, p. 607-623.

Research output: Contribution to journalReview article

Ghanem, Hady ; Kantarjian, Hagop ; Cortes, Jorge ; Quintás-Cardama, Alfonso ; Jabbour, Elias. / Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. In: Expert Opinion on Orphan Drugs. 2013 ; Vol. 1, No. 8. pp. 607-623.
@article{11a6fb5d2bf84ee5af7ae5e92af5f30e,
title = "Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia",
abstract = "Introduction: Chronic myeloid leukemia (CML) is a disease in which outstanding discoveries and achievements have been made over the past two decades. The use of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI) has revolutionized the treatment of this disease and drastically improved its outcomes. Areas covered: Imatinib was the first TKI to be studied and results from the initial IRIS study continues to show major improvement over the historical IFN treatment. More recently, second-generation TKIs, such as dasatinib and nilotinib, and more recently bosutinib proved to be superior to imatinib: higher rates of remission and faster responses. Recently, ponatinib has shown significant efficacy against the most resistant cases of CML, including those who carry the highly resistant T315I mutations. The purpose of this article is to review the data available on different TKIs in the treatment of CML, as well as the emerging data for the treatment of resistant disease. Expert opinion: Early identification of resistant cases and enrollment in clinical trials with new drugs continue to be warranted in the appropriate setting. The use of new therapeutic strategies in an attempt to eradicate the disease will be the main focus of clinical trials in the next decade.",
keywords = "Bosutinib, Chronic myelogenous leukemia, Dasatinib, Imatinib, Nilotinib, Novel therapies, Ponatinib, Tyrosine kinase inhibitors",
author = "Hady Ghanem and Hagop Kantarjian and Jorge Cortes and Alfonso Quint{\'a}s-Cardama and Elias Jabbour",
year = "2013",
month = "1",
day = "1",
doi = "10.1517/21678707.2013.821948",
language = "English (US)",
volume = "1",
pages = "607--623",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

AU - Ghanem, Hady

AU - Kantarjian, Hagop

AU - Cortes, Jorge

AU - Quintás-Cardama, Alfonso

AU - Jabbour, Elias

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Introduction: Chronic myeloid leukemia (CML) is a disease in which outstanding discoveries and achievements have been made over the past two decades. The use of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI) has revolutionized the treatment of this disease and drastically improved its outcomes. Areas covered: Imatinib was the first TKI to be studied and results from the initial IRIS study continues to show major improvement over the historical IFN treatment. More recently, second-generation TKIs, such as dasatinib and nilotinib, and more recently bosutinib proved to be superior to imatinib: higher rates of remission and faster responses. Recently, ponatinib has shown significant efficacy against the most resistant cases of CML, including those who carry the highly resistant T315I mutations. The purpose of this article is to review the data available on different TKIs in the treatment of CML, as well as the emerging data for the treatment of resistant disease. Expert opinion: Early identification of resistant cases and enrollment in clinical trials with new drugs continue to be warranted in the appropriate setting. The use of new therapeutic strategies in an attempt to eradicate the disease will be the main focus of clinical trials in the next decade.

AB - Introduction: Chronic myeloid leukemia (CML) is a disease in which outstanding discoveries and achievements have been made over the past two decades. The use of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI) has revolutionized the treatment of this disease and drastically improved its outcomes. Areas covered: Imatinib was the first TKI to be studied and results from the initial IRIS study continues to show major improvement over the historical IFN treatment. More recently, second-generation TKIs, such as dasatinib and nilotinib, and more recently bosutinib proved to be superior to imatinib: higher rates of remission and faster responses. Recently, ponatinib has shown significant efficacy against the most resistant cases of CML, including those who carry the highly resistant T315I mutations. The purpose of this article is to review the data available on different TKIs in the treatment of CML, as well as the emerging data for the treatment of resistant disease. Expert opinion: Early identification of resistant cases and enrollment in clinical trials with new drugs continue to be warranted in the appropriate setting. The use of new therapeutic strategies in an attempt to eradicate the disease will be the main focus of clinical trials in the next decade.

KW - Bosutinib

KW - Chronic myelogenous leukemia

KW - Dasatinib

KW - Imatinib

KW - Nilotinib

KW - Novel therapies

KW - Ponatinib

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84896734630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896734630&partnerID=8YFLogxK

U2 - 10.1517/21678707.2013.821948

DO - 10.1517/21678707.2013.821948

M3 - Review article

AN - SCOPUS:84896734630

VL - 1

SP - 607

EP - 623

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 8

ER -